© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
Kolliphor P 407, also known to many as poloxamer 407 or Pluronic F127, emerged from research into non-ionic surfactants about seventy years ago. Scientists in the mid-20th century noticed that a family of block copolymers behaved in a unique manner at different temperatures and concentrations. This specific polymer picked up steam for its practical uses in pharmaceutical work, and in time, the cosmetic and chemical industries welcomed it for its flexibility. Unlike many chemical innovations that fade away, it stuck around because of its multiple applications and people’s growing need for reliable, safe excipients. In many ways, its timeline echoes the broader story of synthetic chemistry’s role in making everyday products work better for millions.
This substance stands out because of its structure, which alternates blocks of hydrophilic (water-loving) polyethylene oxide and hydrophobic (water-repelling) polypropylene oxide. Such a profile gives P 407 an unusual quality – it can act as a bridge between oil and water, creating smooth, stable blends. You can find this polymer as a white, waxy substance that dissolves easily in water and forms a clear, viscous gel at modest concentrations. Temperature plays a big role here. At cooler temperatures, it flows like water, but as it warms up, it thickens quickly. That simple change underlies its success in drug delivery, as gels can hold medication close to a target site or help sensitive ingredients reach the patient safely. This sort of versatility doesn’t happen by chance; it ties back to the way scientists have shaped and monitored block copolymer chemistry for decades.
Packaging and regulation standards for Kolliphor P 407 reflect broader rules on pharmaceutical excipients. The labeling on approved lots includes clear naming, expiration dates, and purity grades. Quality and reproducibility matter. Pharmacies, cosmetic labs, and biotech firms need consistency, so suppliers offer details on average molecular weight and the ratio of ethylene oxide to propylene oxide. Specifications usually cover aspects such as residual monomers, heavy metal content, and bacterial endotoxins. The people using poloxamer 407—whether compounding pharmacists, industrial chemists, or researchers—depend on reliable labeling to avoid batch failures and get regulatory clearance for finished products. Any breakdown in quality can disrupt downstream processes, frustrate end-users, and lead to recalls, so strong labeling is a baseline expectation throughout the supply chain.
Synthesis starts with controlled polymerization. Companies mix small units of propylene oxide with initiators and allow chains of polypropylene oxide to grow. Then, polyethylene oxide chains extend from both ends. The entire process calls for clean conditions, careful temperature control, and continuous monitoring. Purification next removes residual chemicals and byproducts. The end result is a copolymer that behaves predictably under countless conditions. Each batch needs assay and verification for chemical structure. From my own lab work, getting reliable polymers requires particular patience and skill—small slip-ups in water content, pH, or batch temperature can ripple through, impacting everything from shelf life to final gel performance. Reliable output depends on precision, not shortcuts.
Chemists often look for ways to tweak Kolliphor P 407 to fit new needs. Attaching functional groups or incorporating new end blocks sometimes gives the polymer added perks—think faster drug release, added responsiveness to certain triggers, or improved mixing with other active compounds. Researchers have played with cross-linking and conjugation, adding moieties that “light up” under UV or break down gently in the body. Most of these changes stick to one core concept: keep the polymer’s base structure intact but sneak in new features that boost performance or safety. These modifications have turned a simple surfactant into a smart tool for gene delivery, antimicrobial gels, and injectable medicines. In R&D, these advances reward creative chemists willing to test boundaries and push their base materials a little further.
Most people bump into Kolliphor P 407 under several names. Some call it poloxamer 407, others refer to Pluronic F127. These words mean much the same. Technical specs or scientific articles may use CAS numbers, but in the real world, users stick to brand names or numbers that show intended grade and purity. The important thing is that buyers, regulators, and lab staff know which grade or synonym matches which project. I’ve seen confusion in purchasing departments and research labs where a simple slip led to the wrong polymer on the bench, throwing off weeks of work. Suppliers and researchers remain careful to match synonyms to end uses, avoiding costly mix-ups and regulatory headaches.
Safe use figures prominently in every stage. Kolliphor P 407 meets pharmaceutical excipient standards for purity, microbial limits, and toxicology. Health agencies like the FDA, EMA, and equivalent national bodies expect clear documentation and full traceability. The excipient must not introduce contaminants or alter drugs’ expected effects. For lab workers, gloves and basic PPE reduce accidental contact, because high concentrations can cause skin or eye irritation. In the environment, breakdown tends to be modest, and risk reports seldom flag it as a major hazard when handled by professionals. That said, bulk storage needs good ventilation, dry conditions, and closed lids to keep the product safe from cross-contamination or spoilage. Companies using it on a large scale keep safety data sheets handy and train new staff, building a blanket of security from plant floor to final customer.
Kolliphor P 407 managed to sneak into countless products—some obvious, others less so. In medicine, it serves as a carrier for drugs that need protection or slow release, and a stabilizer in ointments, creams, and eye drops. I’ve handled it myself in the compounding space, whipping up topical gels or intravenous solutions where other surfactants fail. In cosmetics, it handles foaming and stabilizing for luxury cleansers and high-tech serums. Lab scientists use it to break cells gently or solubilize tough proteins. New uses keep appearing: tissue engineering gels for regenerative medicine, smart coatings for surgical implants, and delivery vehicles for cutting-edge vaccines. The rise of biologics and nanomedicine points squarely at tailored polymers, and P 407 rarely gets left behind when flexibility and safety matter most.
Continuous research brings new life to this decades-old compound. Academic labs dig into polymer science, asking how to tweak physical properties for tougher challenges—think heat stability or clever triggers that release drugs at precise times. Clinical scientists chase bioavailability and patient safety, while engineers look for ways to automate manufacturing and cut batch-to-batch differences. The technology behind poloxamer hydrogels feeds into wound dressings, targeted cancer treatments, and self-healing materials. Media reports and peer-reviewed studies track these experiments, offering tantalizing glimpses at what’s possible. For every published success, a dozen more failures shape choices about which modifications work and which fizzle. Behind the scenes, partnerships between public research institutes and private companies turn bench tricks into commercial-scale wins.
Safety research remains central for a polymer that often ends up in people’s bodies or on their skin. Toxicology work in animals and cell cultures puts Kolliphor P 407 through its paces, seeking allergic reactions, mutagenic effects, or harmful breakdown products. Past studies usually mark low toxicity at approved doses, but the story shifts depending on route and frequency of exposure. Higher doses, especially in animal trials, show potential for disrupting cholesterol and lipid metabolism, raising questions about long-term use in sustained-release formulations. Such results fuel ongoing debates about dose cutoffs and acceptable exposure numbers, especially for vulnerable patients or children. Each new product relying on this polymer must climb a regulatory mountain of toxicology and clinical endpoints, a process that turns arcane chemistry into patient safety.
Its future looks busy. As companies scale up gene therapies, 3D printed tissues, and next-generation biologic drugs, they need carriers and excipients that won’t interfere with fragile ingredients or spark side effects. Kolliphor P 407 answers that call by serving as a trusted platform—but only if product developers and safety officers stay alert to surprises. New research may unlock smarter polymers with even more finely-tuned properties, but the lessons learned from P 407’s history—a blend of adaptability, solid safety, and creativity—won’t vanish. With drug development, nanoscience, and sustainability needs colliding on a global scale, the next wave of uses may come from blending tradition with insight, letting a decades-old surfactant chart new territory where chemistry, medicine, and practical invention meet.
Kolliphor P 407 pops up often in science and health circles, particularly in drug delivery. This name might sound technical, but we're actually talking about a poloxamer — a synthetic substance that brings water-loving and fat-loving parts together in one molecule. That unique structure unlocks a lot of value in the medicine world, especially when drugs struggle to dissolve well.
Pharmacists and researchers don’t choose ingredients without good reason. Drugs rarely dissolve easily in water. Many modern medicines need help getting absorbed by the body. Kolliphor P 407 solves problems here by acting as a solubilizer. I’ve seen injectable and oral medicines work better for actual patients due to this. Cancer drugs, tranquilizers, and some painkillers wouldn’t reach their targets or work as quickly without something that helps them blend with water in the blood. Kolliphor P 407 is the bridge. I remember stories from colleagues about it rescuing stubborn molecules from the fringes of failed research and turning them into real answers for patients.
Step outside the hospital and Kolliphor P 407 plays a part in creams and gels, too. It’s all about texture and release. In personal care, this same ingredient helps turn runny liquids into smooth gels for skincare and wound dressings. Some over-the-counter eye drops, nasal sprays, and hand creams count on it for just the right consistency. That safe, reliable thickening action comes without greasy or sticky residues. I’ve recommended simple gel ointments using it for folks with sensitive skin, knowing the allergy risk stays very low.
Lab technicians and industrial formulators count on Kolliphor P 407. It handles the tough job of working in both water and oil mixtures without breaking down easily in heat. That stability matters everywhere from processing vaccines to stabilizing flavor and color in low-fat food products.
Trust in any medical or health-related ingredient rides on proof and real-life safety records. Kolliphor P 407 has been reviewed by the US Food and Drug Administration and the European Medicines Agency. They highlight its low toxicity at typical doses. Most patients don’t feel side effects at all at regular pharmaceutical levels. Nonetheless, no chemical gets a totally clean bill of health — allergic reactions or local irritation can still show up, especially with high concentrations or if used in open wounds for long periods.
Evidence stacks up in hundreds of peer-reviewed studies. I’ve gone through literature and noticed clear improvements in drug availability and the shelf life of products using it. This links to its predictable structure — chemists know exactly what they’re working with each batch, which supports safety and effect.
Kolliphor P 407 holds a spot in the toolbox, but like any tool, it works best with careful use and regular review. More sensitive diagnostic tests and patient reporting tools help catch rare side effects early. Teaching healthcare staff to look for unusual reactions and keeping options open for allergies will keep public health safe. As demand grows in both pharmaceuticals and everyday consumer goods, ongoing studies will shape how we limit exposure, reduce environmental footprint, and innovate alternatives for people who can’t tolerate certain synthetic additives.
Kolliphor P 407, often listed as poloxamer 407, shows up in all sorts of medications and personal care products. You find it in creams, eye drops, injectables, and more. Plenty of scientists appreciate its ability to blend oil and water and deliver drugs that don’t dissolve easily. Pharmaceutical companies count on it for safer delivery in some tough cases, like chemotherapies where reliable dosing really matters.
Extensive safety testing goes into every ingredient used in drugs—regulators insist on that. Researchers have looked at poloxamer 407 in studies involving animals and people. Data suggests low toxicity when used as directed. Rats fed huge doses showed some changes in blood fat levels, but you won’t find anyone getting anywhere near those doses in a normal pill or gel. For humans, most data comes from clinical trials on the medicines that use it. Skin creams and injected medicines containing the ingredient don’t seem to trigger allergic reactions in most folks. Eye drop formulas using the same base also get a green light.
No one should ignore stories about new ingredients, especially after years of learning what happens with long-term exposure. Poloxamer 407 breaks down in the liver and then gets flushed out with urine. If someone’s liver or kidneys work poorly, doctors keep a close eye on them. There’s also a reason that infants, kids, and pregnant people don’t get lumped in with the general population for drug approvals—vulnerable groups need their own studies, since their bodies process things differently.
Sometimes Kolliphor P 407 doses can stack up in certain medical treatments, especially in intense hospital scenarios. In rare cases where people got high amounts (much higher than over-the-counter or cosmetic products deliver), some had mild cholesterol bumps or stomach complaints. I’ve seen people with sensitive skin or multiple allergies run into issues with almost anything added to a product, even substances listed as safe by regulators. Always helps to check with a doctor if you notice any weird rashes or symptoms after trying something new.
USA and Europe both give Kolliphor P 407 a positive review for the approved uses. The US Food and Drug Administration and the European Medicines Agency keep detailed records of every ingredient in formulated medicines. For every product on shelves, safety testing doesn’t stop with one approval—companies track problems, adverse reports, and complaints. If any pattern emerges, these agencies can ban or restrict use.
Consumers deserve to understand what shows up in their medicine cabinets. Labels don’t always spell out every inactive ingredient. Clearer, more prominent labeling helps those with allergies or chronic illnesses avoid what bothers them. Healthcare pros can use digital records to check for any ingredient flagged as a personal allergy or concern.
Some researchers keep hunting for drug carriers that work even better for people with sensitive systems. Setting tighter guidelines on concentrations for high-risk treatments helps lower any risk. Extra long-term studies can bring new insights as more people come into contact with products containing Kolliphor P 407.
Kolliphor P 407 helps deliver better, more stable medicines. For most people, it works safely inside a wide range of products. No one wants surprises in their healthcare, so ongoing tracking and open communication matter just as much as new science. If you’ve ever worried about an ingredient, talk openly with your doctor and don’t be afraid to read the fine print on what you use every day.
Kolliphor P 407 goes by plenty of names in labs and pharma circles. Some call it poloxamer 407, some know it as Pluronic F127. BASF developed this unique polymer, and it’s been bending the rules in pharmaceutical, cosmetic, and even food science. Essentially, it’s a block copolymer where ethylene oxide and propylene oxide straddle each other in a repeating pattern, creating a flexible yet stable structure.
Take a closer look at the formula: polyethylene oxide (PEO) and polypropylene oxide (PPO) form this block copolymer. A typical poloxamer molecule looks like this: PEOx–PPOy–PEOx. For Kolliphor P 407, the central PPO block sits between two hydrophilic PEO blocks. In numbers, you’re staring at roughly 101 units of ethylene oxide on each end, and 56 units of propylene oxide in the middle. The balance between hydrophilic and hydrophobic bits makes it a kind of chemical multi-tool. If you check out its label, you’ll spot its CAS number, 9003-11-6, ringing some bells in material safety offices and research labs alike.
With its unique structure, Kolliphor P 407 handles water and oil like an old pro. It acts as a surfactant, not just blending oil into water, but also forming micelles that wrap up drugs and nutrients, improving how they travel inside the body or into the skin. That micelle action increases the solubility of hard-to-dissolve compounds, helping medicines get exactly where they’re needed.
Hospitals and clinics have used formulations with poloxamer 407 for decades. It pops up in injectable drugs, gels, and creams. In my small-time experience working on topical pain gels for a biotech startup, I saw how pivotal P 407 proved—its thermal gelation helped turn liquid medicine into a gel at body temperature, ensuring a slow, steady release. This sort of property gives it a special slot when crafting sustained-release injectables or wound dressings.
As popular as it is, Kolliphor P 407 doesn’t escape scrutiny. Its safety record shows most people tolerate it well, both topically and in injected doses. Regulators expect manufacturers to check every batch for residual chemicals left over from synthesis—people deserve to know what’s in their medicine, right down to the last bit. Researchers also keep an eye out for environmental residues, since the polymer resists natural breakdown, raising questions about long-term ecological effects.
Talk of greener chemistry pops up more and more these days. Producers have started looking at using less energy-intensive methods, and sourcing starting materials more responsibly. Keeping an eye on both the origin and end-of-life cycle of ingredients is key in the twenty-first century.
Kolliphor P 407 has already found neat ways to improve how we deliver drugs, boost skincare products, and solve a bunch of tough formulation problems. Scientists aren’t slowing down—researchers scan for alternatives but few match the combo of solubilizing power and safety this polymer offers. Still, ensuring purity and responsible production should always stay at the forefront. With open-label studies and post-market surveillance, both users and companies can keep pace with science and with everyday concerns about what goes into our products and, ultimately, our environment.
From working in the pharmaceutical field, I’ve handled more excipients than I can count, and Kolliphor P 407 stands out due to its versatility. Most labs keep a steady supply on hand, so storing it properly isn’t some abstract concern. Poor storage leads to caked material or even mold—two things that slow down work in any lab.
Kolliphor P 407, known in some circles as Poloxamer 407, comes in a waxy, granular form. Left exposed to air or humidity for too long, it clumps together fast. Moisture is a silent saboteur here. To keep the product flowing and useable, store it in sealed containers away from water sources. Keeping it sealed isn’t about following a checklist—it’s about protecting every batch and every result downstream.
Temperature control makes a difference. I’ve seen people leave it sitting in warm storerooms that were more comfortable for humans than for poloxamers. At higher temperatures, this compound softens and becomes hard to handle, even sticky at times. Place it in a cool spot—specifically between 15 and 30 degrees Celsius. Normal room temperature rarely causes problems, unless airflow is poor or the space heats up over weekends or holidays.
Avoiding cold extremes matters, too. If you stick Kolliphor P 407 in a refrigerator or let it drop below temperatures it’s built for, it stiffens and loses that easy-to-measure, pourable texture. I’ve walked into labs where technicians wasted time chipping at a block of frozen surfactant because someone thought cooler was always better. No one benefits from wasted product or time spent restoring just the right consistency.
In my experience, original packaging always beats makeshift containers. The folks producing Kolliphor P 407 know what keeps their material sound—multi-layered drums or special liners do a much better job than coffee cans or plastic bags from a previous batch. Every time the container opens, it picks up some moisture from the air, so only take what you need and reseal quickly and tightly. Humidity in storerooms creeps up fast, and even brief exposure under humid conditions can spoil a whole batch.
Dry cabinets, silica gel packs, or dedicated chemical storerooms help keep things tidy. Where budgets allow, climate control in chemical storage makes a decisive difference—especially during humid summer months.
Every scoop should be clean—no cross-contamination with leftover powder from other projects. I’ve seen entire lots go back to the supplier because of careless handling. Label every container with opening dates and initials. Small steps like this hold everyone accountable and avoid awkward investigations months later when a stability test fails.
Quality in pharmaceuticals and food applications depends a lot on simple habits. Storing Kolliphor P 407 with care isn’t just about following rules. It’s about safety for users. Spoiled material ruins experiments, drives up costs, and erodes trust in lab results. The best scientists I’ve worked with treat basic storage as a foundation for everything that comes next.
No matter the lab or plant size, solid habits keep Kolliphor P 407 in peak condition. Smart storage preserves not just your investment, but confidence in every capsule, gel, or formula that passes through your hands.
Kolliphor P 407, often called poloxamer 407, has shown up in labs and clinics as an excipient with some clever properties. It looks like an unassuming powder, but once it hits water, it pulls off a neat trick: at certain concentrations and temperatures, it forms a gel. This ability brings up a lot of possibilities, especially in drug delivery where controlling the release of medicine and keeping it stable matter a lot.
Injectable drugs face tough challenges. Stability and safety stand at the top. Kolliphor P 407 comes up as a potential solution for both. Its surfactant properties help dissolve drugs that can’t play nice with water, like some anticancer agents or painkillers. By forming micelles, it kind of sweeps less soluble compounds into tiny molecular pockets, letting doctors deliver drugs via injection that otherwise wouldn’t work.
There have been licensed injectable products containing poloxamer 407. In clinical practice, one example is paclitaxel formulations, where Kolliphor P 407 replaced more aggressive solubilizers. In my own experience working alongside hospital pharmacists, switching to excipients with milder side-effect profiles lowers the chance of reactions at the injection site and cuts down on allergy risks.
Concerns about toxicity always come up for anything heading directly into the bloodstream. Poloxamer 407 has a decent safety record. Studies show that adverse reactions appear rare when sticking within clinically tested concentrations. Still, nothing’s risk-free. There have been cases of vascular irritation and cholesterol alterations at high doses in animal models. Tossing in new excipients without thinking long-term can backfire.
Human studies keep shedding light on dosing and compatibility. Pharmacists and formulators stick close to established regulatory guidelines. The US Pharmacopeia includes Kolliphor P 407 among pharmaceutical excipients used for parenteral products, and the FDA keeps tabs on permissible concentrations based on accumulated evidence. People working in hospitals rely on these guardrails, not gut instinct, when prepping patient-ready injections.
Poloxamer 407 brings convenience and flexible design, but some headaches too. For example, temperature sensitivity means storage and shipping need smart planning. Accidentally gelling at the wrong time can destroy an entire batch. There’s also the issue of long-term stability. Some drugs lose their punch when trapped in polymers for too long. In smaller hospital compounding settings, careful checks and consistent training help head off mistakes.
I’ve seen that training makes the difference between a safe, easy-to-use injectable and a risky one. Teams using Kolliphor P 407 need clear guidelines. Putting effort into batch records and sample testing reduces the chance of dosing errors.
Researchers haven’t run out of ideas. Kolliphor P 407’s thermoresponsive gel comes up often in new approaches, like depot injections, where a shot under the skin slowly releases medicine over weeks. This could change the game for patients who struggle with daily or frequent dosing—think diabetes or cancer medications.
What keeps the excitement going is real-world impact: making stronger, safer formulations that improve lives. Kolliphor P 407, in the hands of cautious professionals working with good data, opens new doors in injectable therapies.
| Names | |
| Preferred IUPAC name | α-Hydro-ω-hydroxypoly(oxy-1,2-ethanediyl), block polymer with 1,2-ethanediyl diacetate |
| Other names |
Poloxamer 407 Pluronic F127 Lutrol F 127 Synperonic PE/F 127 |
| Pronunciation | /ˈkɒlɪfɔːr pi fɔː ˈsɪvən/ |
| Identifiers | |
| CAS Number | 9003-11-6 |
| Beilstein Reference | 3951626 |
| ChEBI | CHEBI:60190 |
| ChEMBL | CHEMBL1201562 |
| ChemSpider | 73040712 |
| DrugBank | DB11097 |
| ECHA InfoCard | ECHA InfoCard: 100943-100-4 |
| EC Number | 9003-11-6 |
| Gmelin Reference | 60468 |
| KEGG | C10459 |
| MeSH | Polyethylene Glycols |
| PubChem CID | 24893585 |
| RTECS number | TR4827500 |
| UNII | 68Y4CF58T6 |
| UN number | UN3082 |
| CompTox Dashboard (EPA) | DTXSID7045477 |
| Properties | |
| Chemical formula | (C2H4O)n(C3H6O)m(C2H4O)n |
| Molar mass | ~12,600 g/mol |
| Appearance | White, coarse powder or free-flowing white granules |
| Odor | Odorless |
| Density | 1.01 g/cm³ |
| Solubility in water | Freely soluble in water |
| log P | 2.69 |
| Basicity (pKb) | > 7 – 9 (1% in water, 20°C) |
| Magnetic susceptibility (χ) | -9.05 × 10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.450 – 1.460 |
| Viscosity | 400 mPa·s to 4,000 mPa·s (5% in water, 25°C) |
| Dipole moment | 1.33 D |
| Pharmacology | |
| ATC code | A06AD15 |
| Hazards | |
| Main hazards | Causes serious eye irritation. |
| GHS labelling | GHS labelling: Not a hazardous substance or mixture according to the Globally Harmonized System (GHS). |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | No hazard statements. |
| Precautionary statements | P264, P280, P305+P351+P338, P337+P313 |
| NFPA 704 (fire diamond) | Health: 1, Flammability: 1, Instability: 0, Special: - |
| Flash point | > 103 °C |
| Autoignition temperature | > 370°C |
| Lethal dose or concentration | LD50 Oral - Rat - > 5,000 mg/kg |
| LD50 (median dose) | > 5700 mg/kg (rat, oral) |
| NIOSH | PY8030000 |
| PEL (Permissible) | 1000 mg/m³ |
| REL (Recommended) | 5-30% |
| IDLH (Immediate danger) | No IDLH established. |
| Related compounds | |
| Related compounds |
Kolliphor P 188 Kolliphor P 124 Kolliphor P 338 Kolliphor RH 40 Kolliphor EL |
